|
|
|
| Comparison of the effects of Fudosteine and N-acetylcysteine on chronic obstructive pulmonary disease complicated with pulmonary fibrosis |
| BAO Li-juan1 , ZHENG Jin-xu2 |
| (1. Department of Respiration, Jintan Hospital Affiliated to Jiangsu University, Jintan Jiangsu 213200; 2. Department of Respiration, the Affiliated Hospital of Jiangsu University, Zhenjiang Jiangsu 212001, China) |
|
|
|
|
Abstract Objective: To investigate the effect of long-term oral administration of fudosteine and N-acetylcysteine on chronic obstructive pulmonary disease (COPD) complicated with pulmonary fibrosis. Methods: Each 60 patients with COPD, COPD complicated with pulmonary fibrosis patients and healthy subjects were selected as the COPD-group, the complicated-group and the control-group, respectively. The eight indicators,which were interleukin-1, interleukin-8, laminin, hyaluronic acid, FVC percent predicted (FVC%pred), the first one second forced expiratory volume percent predicted (FEV1%pred), first second vital capacity, forced expiratory volume occupancy percentage (FEV1/FVC), and carbon monoxide diffusing capacity percent predicted (DLCO%pred) in the three groups were detected. The St George′s Respiratory Questionnaire (SGRQ) and high-frequency CT (HRCT) in COPD-group and complicated-group were surveyed and examed. Then the COPD-group and complicated-group were equally randomized into 3 groups respectively, non-intervention-COPD group, fudosteine-COPD-group, N-acetylcysteine-COPD-group, non-intervention-complicated-group, fudosteine-complicated group,N-acetylcysteine-complicated group. Fudosteine group and N-acetylcysteine group were recepted oral adminstration of fudosteine 0.4 g and N-acetylcysteine 0.6 g,respectively, 3 times per day, for six months. The non-intervention-group, fudosteine-group and N-acetylcysteine-group were retested these indicators and examination. Results: Compared with the control group, COPD group and complicated group showed higher levels of interleukin-1, interleukin-8, laminin, hyaluronic acid (P<0.05), which in the complicated group were significantly higher than the COPD group (P<0.05); while with lower levels of FEV1%pred, FVC%pred, FEV1/FVC, DLCO%pred (P<0.01), which in the fudosteine group were significantly lower than the COPD group (P<0.05). Compared with non-interventione group, fudosteine group and N-acetylcysteine group showed higher levels of interleukin-1, interleukin-8, laminin and hyaluronic acid, higher levels of FEV1%pred, FVC%pred, DLCO%pred; meanwhile, quality of life was improved significantly, imaging performed significantly better under HRCT. The changes in fudosteine group were more obvious than in N-acetylcysteine group(P<0.05). Conclusion: Long-term oral administration of fudosteine and N-acetylcysteine could delay the progress of COPD, and improve COPD patients with pulmonary fibrosis. The therapeutic effect of fudosteine was stronger than -acetylcysteine.
|
|
Received: 03 January 2014
|
|
|
|
| [1]唐勇军，胡成平. 慢性阻塞性肺疾病合并肺间质纤维化临床分析\[J\]. 中国现代医学杂志，2006，16(3)：449-451.［2］左孟华，于振香，吕晓红，等. 大剂量富露施对老年慢性阻塞性肺病合并肺间质纤维化患者的临床研究\[J\]. 中国老年学杂志，2008，28(4)：368-369.［3］Global Executive Commietee. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (revised 2011)\[EB/OL\]. (2011-12-30)\[2012-01-02\]http://www.goldcopd.com.［4］徐凌，蔡柏蔷. N-乙酰半胱氨酸在肺部疾病中的应用进展\[J\]. 国外医学：呼吸系统分册，2004，24(6)：413-416.［5］李华英，陈秀贵. N-乙酰半胱氨酸治疗慢性阻塞性肺疾病患者疗效和作用机制研究\[J\].中国临床药理学与治疗学，2005，10(12)：1423-1426.［6］姜宗培，余学清，陈雄辉，等. 转化生长因子β1对系膜细胞纤溶酶原激活物抑制物1表达的影响\[J\]. 中华肾脏病杂志，2004，20（4）：260-263.［7］陈光. 福多司坦的药理及临床试验\[J\]. 泰州职业技术学院学报，2009，9(6)：35-38.［8］方申存，张映铭，张海涛. 福多司坦对慢性阻塞性肺病激素敏感性的影响\[J\]. 临床肺科杂志，2013，18(1)：29-30.［9］周向东. 慢性气道炎症黏液高分泌药物治疗的现状及研究进展\[J\]. 国外医学：内科学分册，2005，32(3)：115-118，138. |
|
|
|
2014, Vol. 24 
